Download PDF
Thromb Haemost 1994; 72(01): 098-104
DOI: 10.1055/s-0038-1648819
Original Article
Schattauer GmbH Stuttgart

Comparative Thrombolytic Properties of Tissue-Type Plasminogen Activator and of a Plasminogen Activator Inhibitor-1 -Resistant Glycosylation Variant, in a Combined Arterial and Venous Thrombosis Model in the Dog

Désiré Collen
1   The Center for Molecular and Vascular Biology, University of Leuven, Belgium
,
Jean-Marie Stassen
1   The Center for Molecular and Vascular Biology, University of Leuven, Belgium
,
Tsunehiro Yasuda
2   Division of Cardiology, Massachusetts General Hospital Harvard Medical School, Boston, MA, USA
,
Canio Refino
3   Department of Cardiovascular Pharmacology, Genentech Inc, South San Francisco, CA, USA
,
Nicholas Paoni
3   Department of Cardiovascular Pharmacology, Genentech Inc, South San Francisco, CA, USA
,
Bruce Keyt
3   Department of Cardiovascular Pharmacology, Genentech Inc, South San Francisco, CA, USA
,
Tania Roskams
4   Department of Pathology, University of Leuven, Belgium
,
J Luis Guerrero
2   Division of Cardiology, Massachusetts General Hospital Harvard Medical School, Boston, MA, USA
,
Henri R Lijnen
1   The Center for Molecular and Vascular Biology, University of Leuven, Belgium
,
Herman K Gold
2   Division of Cardiology, Massachusetts General Hospital Harvard Medical School, Boston, MA, USA
,
William F Bennett
3   Department of Cardiovascular Pharmacology, Genentech Inc, South San Francisco, CA, USA
› Author Affiliations
Further Information

Publication History

Received 16 February 1994

Accepted after revision 24 March 1994

Publication Date:
12 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

rt-PA-K, a variant of recombinant tissue-type plasminogen activator (rt-PA) with substitution of amino acids 296 to 299 with alanine (KHRR296-299AAAA) has increased fibrin-specificity and reduced sensitivity to plasminogen activator inhibitor-1; rt-PA-T, with threonine 103 replaced by asparagine has an additional glycosylation site and a reduced clearance; and rt-PA-N, with asparagine 117 mutagen-ized to glutamine lacks the high mannose carbohydrate side chain. We have investigated whether combination of these properties in a single molecule might yield an improved thrombolytic agent.

The thrombolytic potency and fibrin-specificity of the combination mutant rt-PA-TNK was compared with that of rt-PA in a combined venous whole blood clot model and platelet-rich arterial eversion graft thrombosis model in dogs given intravenous heparin and aspirin. Infusion of 0.125 to 1.0 mg/kg over 60 min in groups of 4 to 5 dogs produced dose-dependent fibrin-specific venous clot lysis. The thrombolytic potency (percent lysis per mg compound administered per kg body weight) of rt-PA-TNK was significantly higher than that of rt-PA as evidenced by a higher maximal rate of lysis of 480 ± 100% versus 140 ± 40% within the 2 h observation period per mg of compound administered per kg body weight (mean ± SEM, p = 0.004) and a significantly lower dose of 0.08 ± 0.01 versus 0.21 ± 0.04 mg/kg body weight at which the maximal rate of lysis was obtained (p = 0.004). This higher thrombolytic potency was the result of a significantly reduced clearance (240 ± 32 versus 540 ± 49 ml/min, p = 0.002) and a similar specific thrombolytic activity (percent lysis per |ig/ml plasma antigen level). Arterial reflow was obtained with 1 mg/kg rt-PA and with 0.5 mg/kg rt-PA-TNK, but with each agent recanalization was consistently associated with cyclic reocclusion and reflow. The frequency of arterial recanalization was somewhat higher with rt-PA-TNK (10/12) than with rt-PA (4/12) (p = 0.07) but the total patency times during a 2 h observation period were similar.

 

  • References

  • 1 The Gusto Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682
    PubMedGoogle Scholar
  • 2 The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-1632
    PubMedGoogle Scholar
  • 3 Larsen GR, Metzger M, Henson K, Blue Y, Horgan P. Pharmacokinetics and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. Blood 1989; 73: 1842-1850
    PubMedGoogle Scholar
  • 4 Browne MJ, Carey JE, Chapman CG, Tyrrell AWR, Entwisle C, Lawrence GMP, Reavy B, Dodd I, Esmail A, Robinson JH. A tissue-type plasminogen activator mutant with prolonged clearance in vivo. Effect of removal of the growth factor domain. J Biol Chem 1988; 263: 1599-1602
    PubMedGoogle Scholar
  • 5 Hotchkiss A, Refino CJ, Leonard CK, O’Connor JV, Crowley C, McCabe J, Tate K, Nakamura G, Powers D, Levinson A, Mohler M, Spellman MW. The influence of carbohydrate structure on the clearance of recombinant tissue-type plasminogen activator. Thromb Haemost 1988; 60: 255-261
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Krause J. Catabolism of tissue-type plasminogen activator (t-PA), its variants, mutants and hybrids. Fibrinolysis 1988; 2: 133-142
    PubMedGoogle Scholar
  • 7 Lijnen HR, Collen D. Strategies for the improvement of thrombolytic agents. Thromb Haemost 1991; 66: 88-110
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Collen D, Stassen JM, Larsen G. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. Blood 1988; 71: 216-219
    PubMedGoogle Scholar
  • 9 Collen D, Lijnen HR, Vanlinthout I, Kieckens L, Nelles L, Stassen JM. Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model. Thromb Haemost 1991; 65: 174-180
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Kruithof EKO, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913
    PubMedGoogle Scholar
  • 11 Madison EL, Goldsmith EJ, Gerard RD, Gething MJH, Sambrook JF. Ser-pin-resistant mutants of human tissue-type plasminogen activator. Nature 1989; 339: 721-724
    CrossrefPubMedGoogle Scholar
  • 12 Madison EL, Goldsmith EJ, Gerard RD, Gething MJH, Sambrook JF, Bas-sel-Duby RS. Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. Proc Natl Acad Sci USA 1990; 87: 3530-3533
    CrossrefPubMedGoogle Scholar
  • 13 Bennett WF, Paoni NF, Keyt BA, Botstein D, Jones AJS, Presta L, Wurm FM, Zoller MJ. High resolution analysis of functional determinants on human tissue-type plasminogen activator. J Biol Chem 1991; 266: 5191-5201
    PubMedGoogle Scholar
  • 14 Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, Lai J, Pena L, Pater C, Ogez J, Etcheverry T, Botstein D, Bennett WF. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994; 91: 3670-3674
    CrossrefPubMedGoogle Scholar
  • 15 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
    CrossrefPubMedGoogle Scholar
  • 16 Zamarron C, Lijnen HR, Van Hoef B, Collen D. Biological and thrombolytic properties of proenzyme and active forms of human urokinase. I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology. Thromb Haemost 1984; 52: 19-23
    PubMedGoogle Scholar
  • 17 Jang IK, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, May JN, Collen D. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79: 920-928
    PubMedGoogle Scholar
  • 18 Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM. Thrombolytic and pharmacokinetic properties of chimeric (tissue-type/urokinase-type) plasminogen activator. Circulation 1991; 84: 1216-1234
    CrossrefPubMedGoogle Scholar
  • 19 Kominger C, Matsuo O, Suy R, Stassen JM, Collen D. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis. J Clin Invest 1982; 69: 573-580
    CrossrefPubMedGoogle Scholar
  • 20 Giles AR. Guidelines for the use of animals in biomedical research. Report of the Subcommittee on Animal Models of Haemorrhagic and Thrombotic Disorders. Scientific and Standardization Committee. The International Society of Thrombosis and Haemostasis. Thromb Haemost 1987; 58: 1078-1084
    PubMedGoogle Scholar
  • 21 Refino C, Keyt B, Paoni N, Badillo J, Pater C, Van Peborgh J, Pena L, Berleau L, Nguyen H, Bennett W. A variant of tissue plasminogen activator (T103N, N117Q, KHRR296-299AAAA) with a decreased plasma clearance rate, is substantially more potent than Activase rt-PA in a rabbit thrombolysis model. Thromb Haemost 1993; 69: 841 (Abstr 1074)
    PubMedGoogle Scholar
  • 22 Friedman M, van den Bovenkamp GJ. The pathogenesis of a coronary thrombus. Am J Pathol 1966; 48: 19-44
    PubMedGoogle Scholar
  • 23 Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischaemic death and crescendo angina. Br Heart J 1985; 53: 363-373
    CrossrefPubMedGoogle Scholar
  • 24 Yasuda T, Gold HK, Leinbach RC, Saito T, Guerrero JL, Jang I-K, Holt R, Fallon JT, Collen D. Lysis of plasminogen activator-resistant platelet-rich coronary arterial thrombus with combined bolus injection of recombinant tissue-type plasminogen activator (rt-PA) and antiplatelet GPIMIIa antibody. J Am Coll Cardiol 1990; 16: 1728-1735
    CrossrefPubMedGoogle Scholar
  • 25 Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA, Collen D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIMIIa antibody in a canine preparation. Circulation 1988; 77: 670-677
    CrossrefPubMedGoogle Scholar
  • 26 Yasuda T, Gold HK, Leinbach RC, Yaoita H, Fallon JT, Guerrero L, Napier MA, Bunting S, Collen D. Kistrin, a polypeptide platelet GPIMIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation. Circulation 1991; 83: 1038-1047
    CrossrefPubMedGoogle Scholar